News

AddToAny

Google+ Facebook Twitter Twitter

Chlamydia vaccine on horizon

The first ever chlamydia vaccine to reach phase 1 clinical trial has been found to be safe and able to provoke an immune response.

The randomised controlled trial of 35 healthy women demonstrates promising early signs of what could be an effective vaccine.

However, further trials are required to determine whether the immune response it provokes effectively protects against chlamydia infection.

Chlamydia, caused by the bacterium Chlamydia trachomatis, presents a major global health burden, with 131 million new cases occurring annually. 

But as three out of four infections are symptomless, this number is likely to be underestimated. The most new cases are found in teenagers and young adults.

Vaccination may be the best way to tackle the epidemic, as national treatment programmes have largely failed to curb the epidemic, despite availability of diagnostic tests and effective antibiotic treatment. 

Image credit | iStock

Related Articles

Slime of the times

Sarah J Pitt and Alan Gunn write about their search for new antibiotics, which has taken them out of the laboratory and into the vegetable patch. 

December news in numbers

A breakdown of science news this month, in numbers.

A case study: transport perfusion fluid

Daniel Weiand, Consultant Microbiologist and Educational Lead, reflects on the role of abdominal organ transport perfusion fluid culture.

New test for chronic hepatitis B

A new laboratory tool may improve the diagnosis and treatment of hepatitis B virus (HBV) infection. 

Top